Skip over global navigation links

Office of the Assistant Secretary for Preparedness and Response

PHE Home > PHE Newsroom

HHS Accelerates Clinical Trials, Prepares for Manufacturing of COVID-19 Vaccines

BARDA is supporting multiple products to accelerate the development of medical countermeasures. BARDA will bring our full expertise to partners for advanced clinical trials of 2 products and secure domestic manufacturing of vaccines to prevent COVID-19.
HHS accepts donations of medicine to Strategic National Stockpile as possible treatments for COVID-19 patients

HHS accepted and FDA issued an emergency use authorization for 30 million doses of donated medicines from Sandoz and Bayer for possible use in treating patients hospitalized with COVID-19 or for use in clinical trials. The drugs are approved for use in treating malaria and other diseases.
HHS Provides $100 Million to Help U.S. Healthcare Systems Prepare For COVID-19 Patients

Hospitals and healthcare workers are on the front lines of the COVID-19 pandemic. To help them respond rapidly and safety, HHS is providing $100 million to create a National Special Pathogen System, leveraging existing public health and health care infrastructure and capabilities, as well as expertise from the U.S. Ebola response.
HHS, DoD collaborate with Cepheid on rapid diagnostics to detect coronavirus infections

A rapid diagnostic test for COVID-19 has received advanced development support through a collaboration between BARDA, JPEO-CBRND, and Cepheid. The test can provide results within 45 minutes, and is designed for use in clinical and hospitals laboratories.
HHS Funds Phase 2/3 Clinical Trial for Potential Treatment for COVID-19

BARDA is supporting a Phase 2/3 clinical trial for an antibody medicine being evaluated to treat severe cases of COVID-19, which are being conducted by Regeneron. Through this public-private partnership, we are working to develop potentially life-saving therapeutics rapidly.